Volume 21, Number 11—November 2015
CME ACTIVITY - Synopsis
Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E
Table 3
Disorder | Age, y (range) | Sex ratio | AST, IU/L (± SD) | ALT, IU/L (± SD) | PT, % (± SD) | Bilirubin, μmol/L (± SD) | ALKP, IU/L (± SD) | GGT, IU/L (± SD) |
---|---|---|---|---|---|---|---|---|
MM | 54 (25–77) | 1 | 150 (± 200)† | 835 (± 1,396) | 92.8 (± 7.5) | 25.6 (± 32) | 328.5 (± 198) | 166.2 (± 95)† |
PTS | 55 (51–56) | 6 | 740.7 (± 503) | 1,401.25 (± 647) | 94.5 (± 4.9) | 22.2 (± 13) | 355 (± 211) | 476.5 (± 245) |
MR | 54 (33–74) | 2 | 687.7 (± 915) | 544.67 (±288) | 91.3 (± 13.3) | 38.9 (± 54) | 358.67 (± 305) | 248.3 (± 253) |
AIDP | 57 (54–60) | 1 | 75 (± 54) | 216 (± 236) | 97 (± 4) | 20.6 (± 19) | 281 (± 272) | 415 (± 519) |
*AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; ALKP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; MM, mononeuritis multiplex; PTS, Parsonage-Turner syndrome; MR, meningoradiculitis; AIDP, acute inflammatory demyelinating polyradiculoneuropathy.
†p<0.05 when compared with PTS.
Page created: October 19, 2015
Page updated: October 19, 2015
Page reviewed: October 19, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.